X-Waiver Changes Axed: Federal Government Backtracks on Previously Announced Rescission of Waiver Requirements
February, 2021 - Daniel Zinsmaster, Christopher Begin
In the waning days of the Trump administration, HHS announced a plan to expand practitioner ability to provide MAT to patients suffering from opioid use disorder. Citing the opioid epidemic’s toll on public health and the staggering recent amount of overdose deaths,[iii] HHS sought to modify the requirement that eligible practitioners must have the waiver before prescribing buprenorphine to patients with OUD.[iv] The elimination of or exemption from the X-Waiver requirement would have only applied to physicians, who would then be limited to treating no more than 30 patients at any one time.
The announcement, made on Jan. 14, 2021, six days before the inauguration of the Biden administration, left HHS little time to implement any meaningful changes. Although HHS published its notice in the Federal Register and indicated further guidance would be forthcoming, no such guidance was ever released. On Jan. 27, 2021, the Biden administration announced its cancellation of changes to the X-Waiver program. Declaring HHS’s announcement of the change as “premature,” the White House nevertheless pledged to increase practitioner access to buprenorphine.
The reversal notwithstanding, there are questions as to whether HHS could have legally made these changes to the X-Waiver program, even if the change was made in a timely and meaningful fashion. The X-Waiver requirement was created by an act of Congress, namely, Section 3502 of the Children’s Health Act of 2000 (Act).[v] The HHS secretary’s authority to issue practical guidelines – like the one issued on Jan. 14, 2021 – is contained in § 823(g)(2)(H)(i)(II) of the same act. But while the secretary may issue practical guidelines to exempt certain requirements and regulations, the secretary’s ability override statutorily defined conditions on dispensing these narcotic drugs is suspect. A regulatory promulgation cannot override a statutory enactment.
Despite the reversal, broad support for the elimination of the X-Waiver requirement may see it revived in the future. United States Senators Maggie Hassan (D-N.H.) and Lisa Murkowski (R-Alaska) plan to introduce a bill to eliminate the X-Waiver requirement. However, as of right now, the X-Waiver is still required for the prescribing of buprenorphine-containing products for OUD.
Should you have questions concerning the recent X-Waiver developments or the appropriate provision of MAT to patients suffering from OUD, please contact a member of Dinsmore’s Health Care practice group.
[i] Buprenorphine is a FDA-approved OUD treatment that acts as an opioid partial agonist by producing weaker euphoria and respiratory depression effects than full opioid agonists such as methadone and heroin. https://www.samhsa.gov/medication-assisted-treatment/medications-counseling-related-conditions/buprenorphine.
[ii] Medication and Counseling Treatment, Substance Abuse and Mental Health Services Administration, https://www.samhsa.gov/medication-assisted-treatment/treatment#medications-used-in-mat (last visited Feb. 4, 2021).
[iii] The Centers for Disease Control and Prevention recorded the highest ever number of drug overdose deaths in a 12-month period: 81,000 in the 12 months ending in May, 2020. https://www.cdc.gov/media/releases/2020/p1218-overdose-deaths-covid-19.html.
[v] This section modified the Controlled Substances Act at 21 U.S.C. § 823(g).
Link to article